Clinical Trial Update: Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the combination of rituximab and lenalidomide in previously untreated follicular lymphoma has completed enrollment and posted results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Rituximab (rituximab)

Snippet

Sponsor: Celgene | Conditions: Follicular Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2025-05-14